Skip to content
Government Federal, Medical Health Aged Care

Delving into diabetes

House of Representatives 2 mins read

The broader impacts of diabetes on Australia’s health system and economy, and recent advances in the prevention and management of this significant health condition, will be the focus of a new inquiry by the House Health Committee.

The Chair of the Committee, Dr Mike Freelander MP, stated: ‘Diabetes is the world’s fastest growing chronic health condition, currently impacting approximately 1.3 million Australians. There are multiple forms of diabetes, including type 1, type 2, gestational and other rare types. The Committee looks forward to conducting this inquiry to better understand the current situation regarding diabetes in Australia, including the effectiveness of current Australian Government policies and programs aiming to prevent, diagnose and manage the condition.’

‘The Inquiry will be broad and will also look at lifestyle factors and the interaction between lifestyle, Type 2 diabetes, and obesity’ stated Dr Freelander.

‘The Committee looks forward to hearing from individuals with diabetes, healthcare service providers, researchers, peak bodies, the Australian Government, state and territory governments and members of the public to understand new evidence-based advances in the prevention and management of the condition, and the broader impacts of diabetes on Australia’s health system and economy’ he said.

Submissions from interested individuals and organisations are invited by 31 August 2023. The preferred method of receiving submissions is by electronic format lodged online using a My Parliament account.

Further information about the Committee’s inquiry, including the full terms of reference and details on how to lodge a submission are available at the Committee’s website.

****Media call, 11.30am, Senate Courtyard****

Members of the House of Representatives Standing Committee on Health, Aged Care and Sport will be available at 11.30am today (30 May 2023) to speak about and answer questions on the inquiry.

Media inquiries

Dr Mike Freelander MP
Chair of the House of Representatives Standing Committee on Health, Aged Care and Sport
[email protected]
(02) 4620 0293

For background information

Committee Secretariat
02 6277 4145
[email protected]

 



More from this category

  • Medical Health Aged Care
  • 18/05/2025
  • 08:48
Monash University

How AI can improve dementia detection

Researchers from the National Centre for Healthy Ageing (NCHA), a partnership between Monash University and Peninsula Health, have developed a novel method for improving dementia detection in hospitals by combining traditional methods with artificial intelligence (AI). Approximately 50 million people worldwide live with dementia, a number expected to triple by 2050, according to the World Alzheimer Report. In Australia, there is still a need to substantially improve our methods for counting people with dementia. Accurate Identification is critical to understanding the true size of the problem nationally, and to be able to effectively plan services. However, routine health data that…

  • Medical Health Aged Care
  • 18/05/2025
  • 05:30
Dementia Australia

Join us today for the Melbourne Memory Walk & Jog

What: Dementia Australia’s Melbourne Memory Walk & Jog    When: Sunday, 18 May from 7:30am   Who: More than 2,300 locals participating on the day. People who have been impacted by dementia, their family, friends and carers. Special guests Woody Whitelaw and Takaya Honda.   Where: Princes Park, Carlton North.   Dementia Australia spokespeople and local residents are available for interview. Photos and video of previous Memory Walk & Jog events for publication are available for use. For more information visit: https://www.memorywalk.com.au/event/melbourne/home Dementia Australia is the source of trusted information, education and services for the estimated more than 433,300 Australians living with…

  • Contains:
  • Medical Health Aged Care
  • 17/05/2025
  • 17:11
FUJIREBIO

Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ ß-Amyloid 1-42 Plasma Ratio In-vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease

—First Blood-Based In-Vitro Diagnostic Test to Receive FDA Clearancefor Patients Being Assessed for Alzheimer’s Disease. — —Availability of Accurate, Accessible, Blood-Based Diagnostic Tests Will…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.